货号 | 3996T |
反应种属 | Human,Monkey, |
来源宿主 | Rabbit |
应用 | WB, IF-IC |
目标/特异性 | MSH6 (L990) Antibody detects endogenous levels of total MSH6 protein. |
使用方法 | WB(1:1000) IF-IC (1:50) |
供应商 | CST |
灵敏度 | Endogenous |
背景 | The DNA mismatch repair system (MMR) repairs post-replication DNA, inhibits recombination between nonidentical DNA sequences, and induces both checkpoint and apoptotic responses following certain types of DNA damage (1). MSH2 (MutS homologue 2) forms the hMutS-α dimer with MSH6 and is an essential component of the mismatch repair process. hMutS-α is part of the BRCA1-associated surveillance complex (BASC), a complex that also contains BRCA1, MLH1, ATM, BLM, PMS2 proteins, and the Rad50-Mre11-NBS1 complex (2). Mutations in MSH6 and other MMR proteins have been found in a large proportion of hereditary nonpolyposis colorectal cancer (Lynch Syndrome), the most common form of inherited colorectal cancer in the Western world (3). Mutations in MSH6 have been shown to occur in glioblastoma in response to temozolomide therapy and to promote temozolomide resistance (4).DNA错配修复系统(MMR)能够修复复制后DNA,抑制非相同DNA序列间的重组,诱导伴随某些DNA损伤类型的检验点和凋亡反应(1)。MSH2 (MutS 同源蛋白2)和MSH6组成的hMutS-α二聚体是错配修复过程必不可少的部分。hMutS-α是BRCA1相关监视蛋白复合体(BRSC)的一部分,该复合体还包括BRCA1, MLH1, ATM, BLM, PMS蛋白和Rad50-Mre11-NBS1复合体(2)。在大部分遗传性非息肉性大肠癌(Lynch综合征)中已发现MSH6和其它MMR蛋白的突变,该疾病是西方国家最常见的遗传性结肠癌(3)。研究发现恶性胶质瘤中MSH6发生突变以响应替莫唑胺治疗,并可以促进替莫唑胺抵抗(4)。 |
存放说明 | -20C |
计算分子量 | 160 |
参考文献 | 1 . OBrien, V. and Brown, R. (2006) Carcinogenesis 27, 682-92. 2 . Wang, Y. et al. (2000) Genes Dev 14, 927-39. 3 . Plotz, G. et al. (2006) J Mol Histol 37, 271-83. 4 . Yip, S. et al. (2009) Clin Cancer Res 15, 4622-9. |
Confocal immunofluorescent analysis of HCT-116 cells using MSH6 (L990) Antibody (green). Actin filaments have been labeled using DY-554 phalloidin (red).激光共聚焦免疫荧光方法检测HCT-116 细胞,使用的抗体为MSH6 (L990) Antibody ,呈绿色。肌动蛋白纤维由DY-554鬼笔环肽标记,呈红色。 | |
Western blot analysis of extracts from various cell types using MSH6 (L990) Antibody.Western blot方法检测不同细胞提取物,使用的抗体为MSH6 (L990) Antibody。 |